NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»28/09/2009 [Company watch]
Zhangjiang Hi-Tech Park VC Unit to Buy Stake in Buchang

Shanghai Zhangjiang Hi-Tech Park Development Co. said it will increase its investment in wholly-owned subsidiary Haocheng Venture Capital Co. by 48 million yuan to help Haocheng buy a 0.4 percent stake in Shandong Buchang Pharmaceutical Co.

 
Shanghai Zhangjiang Hi-Tech Park Development Co. said it will increase its investment in wholly-owned subsidiary Haocheng Venture Capital Co. by 48 million yuan to help Haocheng buy a 0.4 percent stake in Shandong Buchang Pharmaceutical Co. In a Sept 23 statement to the Shanghai Stock Exchange, Zhangjiang Hi-Tech said Shenzhen China Euro Capital Co. has signed an agreement to sell the stake. Zhangjiang Hi-Tech investor relations official Xu Lei told Caijing that the stake purchase is in line with the company\'s practice of investing in technology firms in support of its core business of developing industrial parks. Buchang Pharmaceutical, which is preparing for a listing, is starting to integrate the pharmaceutical-related assets of parent Buchang Group. Haocheng Venture Capital has attached a buyback provision in the sale agreement, under which Shenzhen China Euro Capital will be obliged to repurchase the stake if Buchang Pharmaceutical does not list by Dec. 31, 2013. Buchang Group\'s pharmaceutical assets, which include traditional Chinese medicines, booked net profit of 550 million yuan and 700 million yuan in 2007 and 2008 respectively. In 2009 net profit is forecast at 900 million yuan. Zhangjiang Hi-Tech said in an earlier statement that Haocheng plans to invest 198 million yuan to set up a 99 percent-held investment joint venture. Zhangjiang Hi-Tech closed down 2.89 percent at 13.09 yuan on Sept. 23.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.